Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry.

Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, Norris KC.

JAMA Netw Open. 2019 Dec 2;2(12):e1918169. doi: 10.1001/jamanetworkopen.2019.18169.

2.

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD.

Norris KC, Duru OK, Alicic RZ, Daratha KB, Nicholas SB, McPherson SM, Bell DS, Shen JI, Jones CR, Moin T, Waterman AD, Neumiller JJ, Vargas RB, Bui AAT, Mangione CM, Tuttle KR; CURE-CKD investigators.

BMC Nephrol. 2019 Nov 20;20(1):416. doi: 10.1186/s12882-019-1558-9.

3.

Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.

Dieter BP, Daratha KB, McPherson SM, Short R, Alicic RZ, Tuttle KR.

Am J Nephrol. 2019;49(5):359-367. doi: 10.1159/000499574. Epub 2019 Apr 2.

PMID:
30939480
4.

Erratum. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248-257.

Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR.

Diabetes. 2019 May;68(5):1094. doi: 10.2337/db19-er05a. Epub 2019 Apr 1. No abstract available.

5.

Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.

Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR.

Diabetes. 2019 Feb;68(2):248-257. doi: 10.2337/dbi18-0007. Review. Erratum in: Diabetes. 2019 May;68(5):1094.

6.

GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.

Dieter BP, Alicic RZ, Tuttle KR.

Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1519-F1525. doi: 10.1152/ajprenal.00211.2018. Epub 2018 Aug 15. Review.

7.

SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.

Alicic RZ, Johnson EJ, Tuttle KR.

Am J Kidney Dis. 2018 Aug;72(2):267-277. doi: 10.1053/j.ajkd.2018.03.022. Epub 2018 Jun 14. Review.

PMID:
29866460
8.

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.

Alicic RZ, Johnson EJ, Tuttle KR.

Adv Chronic Kidney Dis. 2018 Mar;25(2):181-191. doi: 10.1053/j.ackd.2017.12.002. Review.

PMID:
29580582
9.

Medication Therapy Management after Hospitalization in CKD: A Randomized Clinical Trial.

Tuttle KR, Alicic RZ, Short RA, Neumiller JJ, Gates BJ, Daratha KB, Barbosa-Leiker C, McPherson SM, Chaytor NS, Dieter BP, Setter SM, Corbett CF.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):231-241. doi: 10.2215/CJN.06790617. Epub 2018 Jan 2.

10.

Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Alicic RZ, Rooney MT, Tuttle KR.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18.

11.

Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.

Neumiller JJ, Alicic RZ, Tuttle KR.

J Am Soc Nephrol. 2017 Aug;28(8):2263-2274. doi: 10.1681/ASN.2016121372. Epub 2017 May 2. Review.

12.

Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease.

Dieter BP, McPherson SM, Afkarian M, de Boer IH, Mehrotra R, Short R, Barbosa-Leiker C, Alicic RZ, Meek RL, Tuttle KR.

J Diabetes Complications. 2016 Nov - Dec;30(8):1467-1472. doi: 10.1016/j.jdiacomp.2016.07.018. Epub 2016 Jul 27.

13.

Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics.

Alicic RZ, Short RA, Corbett CL, Neumiller JJ, Gates BJ, Daratha KB, Barbosa-Leiker C, McPherson S, Chaytor NS, Dieter BP, Setter SM, Tuttle KR.

Am J Nephrol. 2016;44(2):122-9. doi: 10.1159/000447019. Epub 2016 Aug 4.

14.

Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.

Dieter BP, Alicic RZ, Meek RL, Anderberg RJ, Cooney SK, Tuttle KR.

Diabetes Spectr. 2015 Aug;28(3):167-74. doi: 10.2337/diaspect.28.3.167.

15.

Novel therapies for diabetic kidney disease.

Alicic RZ, Tuttle KR.

Adv Chronic Kidney Dis. 2014 Mar;21(2):121-33. doi: 10.1053/j.ackd.2014.01.007. Review.

PMID:
24602462
16.

Direct and indirect effects of obesity on the kidney.

Alicic RZ, Patakoti R, Tuttle KR.

Adv Chronic Kidney Dis. 2013 Mar;20(2):121-7. doi: 10.1053/j.ackd.2012.12.006. Review.

PMID:
23439370
17.

Management of the diabetic patient with advanced chronic kidney disease.

Alicic RZ, Tuttle KR.

Semin Dial. 2010 Mar-Apr;23(2):140-7. doi: 10.1111/j.1525-139X.2010.00700.x. Epub 2010 Mar 30. Review.

PMID:
20374553
18.

Should albuminuria be a focus of antihypertensive therapy goals?

Alicic RZ, Saha SA, Short RA, Tuttle KR.

Curr Hypertens Rep. 2009 Oct;11(5):354-62. Review.

PMID:
19737452

Supplemental Content

Loading ...
Support Center